Drugs & Pharmaceuticals

Back in March, I gave an update on the progress of otenaproxesul (aka ATB-346), an experimental hydrogen sulfide-based NSAI

It's not at all surprising that CDC data from 2020 shows an increase in drug overdose deaths.

While effective vaccines are an incredibly important part of the COVID-19 solution, none are completely effective, and so we do need 

As Professor Katherine Radtke-Seley and I wrote last year in the Baltimore Sun, vaccines

One of the earliest (of many) bizarre symptoms of COVID-19 was blood clotting in the lungs. These clots could easily be seen when an endotracheal tube was removed from a ventilated patient.

If you're ever in the mood for some yuks, take a casual stroll up and down the aisles in a CVS pharmacy and see if you can't find a bunch of stuff that shouldn't be sold there (maybe even anywhere). It's not that hard.

Back in 2019, I wrote about some of the tricks that drug companies use to hang onto brand name sales even though the drug's generic equivalent may have been around for years, if not decades (See 

The amount of rebates and fees collected by insurers and pharmacy benefit managers (PBMs) drive formulary positions and access for brand name medicines.

This blog was inspired by a recent conversation with a CEO of a clinical phase antibiotic biotech.

For those who follow our bizarre concoction of drug laws, it should come as no surprise that they are both ineffective and also woefully ill-equipped to keep up with new (sometimes) legal analogs that even a marginally trained chemi